Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure

Artificial Organs

Volumn 20, Issue 11, 1996, Pages 1169-1172

  Yoshiba, Makoto ^a   Inoue, Kazuaki ^a   Sekiyama, Kazuhiko ^a   Koh, Ichiu ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Artificial liver support; Plasma exchange

Indexed keywords

PATIENT TREATMENT; VIRUSES;

ARTIFICIAL LIVER; ARTIFICIAL LIVER SUPPORT; ARTIFICIAL LIVER SUPPORT SYSTEMS; BLEEDINGS; FULMINANT HEPATIC FAILURES; FULMINANT HEPATITIS; HEMODIAFILTRATION; PERFORMANCE; PLASMA EXCHANGES; VIRUS INFECTION;

ARTIFICIAL ORGANS;

ARTICLE; ARTIFICIAL LIVER; CLINICAL TRIAL; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; SURVIVAL;

HEPATITIS A VIRUS; HEPATITIS B VIRUS; NON A NON B HEPATITIS VIRUS; NON-A, NON-B HEPATITIS VIRUS;

EID: 0029804658     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1996.tb00657.x     Document Type: Article

References (15)

1. Starzl TE, Demetris AJ, Van Thiel DH. Liver transplantation. New Engl J Med 1989;321:1014-22.
2. Shafer DS, Shaw BW. Fulminant hepatic failure and orthotopic liver transplantation. Semin Liver Dis 1989;9:189-94.
3. Matsunami H, Makuuchi M, Kawasaki S, Ishizone S, Mizusawa Y, Kawarasaki H, Takayama T. Living-related liver transplantation in fulminant hepatic failure. Lancet 1992; 340:1141-2.
4. Yoshiba M, Inoue N, Sanjo T, Yamazaki Z, Okada Y, Oda T, Wada T. Plasmapheresis in acute liver failure. In: Nosé Y, Malchesky PS, Smith JW, Krakauer RS, eds. Plasmapheresis therapeutic applications and new techniques. New York: Raven Press, 1983:399-406.
5. Opolon P. Significance of middle molecules in the pathogenesis of hepatic encephalopathy. In: Kleinberger G, Ferenci P, Reiderer P, Thaler H, eds. Advances in hepatic encephalopathy and urea cycle diseases. Basel, Switzerland: Karger, 1984:301-9.
6. Yoshiba M, Yamada H, Yoshikawa Y, Fujiwara K, Toda G, Oka H, Sanjo T, Yamazaki Z, Idezuki Y, Inoue N, Sakai T, Kunitomo T. Hemodiafiltration treatment of deep hepatic coma by protein passing membrane: Case report. Artif Organs 1986;10:417-21.
7. Yoshiba M, Sekiyama K, Iwamura Y, Sugata F. Development of reliable artificial liver support (ALS): Plasma exchange in combination with hemodiafiltration using high-performance membranes. Dig Dis Sci 1993;38:469-76.
8. Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Shaffner F, eds. Progress in liver diseases: vol. 3. Grune & Stratton, 1970:282-98.
9. Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology. Lancet 1995;346:1131-2.
10. Badalamenti S, Graziani G, Salerno F, Ponticelli C. Hepatorenal syndrome. Ann Intern Med 1993;153:1957-67.
11. Gazzard BG, Weston MJ, Murray-Lyon IM, Frax H, Record CO, Portmann B, Langley PG, Dunlop EH, Mellon PJ, Ward MB, Williams R. Charcoal hemoperfusion in the treatment of fulminant hepatic failure. Lancet 1974;1:1301-7.
12. Denis J, Opolon P, Nusinovici V, Granger A, Darnis F. Treatment of encephalopathy during fulminant hepatic failure by hemodialysis with high permeability membrane. Gut 1978;19:787-93.
13. Silk DBA, Hanid MA, Treby PN, Davies M, Chase RA, Langley PG, Mellon PJ, Wheeler PG, Williams R. Treatment of fulminant hepatic failure by polyacrilonitrile membrane hemodialysis. Lancet 1977;2:1-3.
14. Livingstone AS, Potuin M, Goresky CA, Finlayson MH, Hinchey EJ. Changes in the bloodbrain barrier in hepatic coma after hepatectomy in the rat. Gastroenterology 1977; 73:697-704.
15. Yoshiba M, Sekiyama K, Inoue K, Fujita R. Interferon and cyclosporin A in the treatment of fulminant viral hepatitis. J Gastroenterol 1995;30:67-73.